Clinical Trials · NCT07202884
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 1,000
- Start date
- Sep 2025
- Locations
- 137 sites, 10 countries
- Primary endpoint
- Change from Baseline in Incontinence Episode Frequency (IEF)